Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS Cancer Drugs as Biotech Sector Heats Up

on

Revolution Medicines announced a $2 billion flexible funding agreement with Royalty Pharma on June 24, 2025, including up to $1.25B in synthetic royalties on daraxonrasib sales and $750M in debt.12

The deal supports independent global development and commercialization of RAS(ON) inhibitors like daraxonrasib for NSCLC and PDAC, without needing a Big Pharma partner.12

Revolution received the first $250M tranche immediately, with more tied to milestones like Phase 3 PDAC study success; royalties start at 4.55% on first $2B sales.12

Company ended March with $2.1B cash, now extending runway significantly and pursuing global commercialization strategy.12

Query mentions XBI reaching pandemic highs, signaling strong biotech market sentiment amid this financing news, though specifics on XBI not detailed in sources.6

Sources:

1. https://www.fiercebiotech.com/biotech/royalty-signs-2b-bankroll-revolutions-ras-cancer-drugs-road-approval

2. https://www.biospace.com/press-releases/revolution-medicines-enters-into-2-billion-flexible-funding-agreement-with-royalty-pharma-to-support-global-development-and-commercialization-of-rason-inhibitor-portfolio-for-patients-with-ras-addicted-cancers

6. https://www.ainvest.com/news/revolution-medicines-2b-upsized-raise-bullish-signal-big-risk-2604/